

June 16, 2015



## Corbus Pharmaceuticals Announces Inclusion in Russell MicroCap(R) Index

NORWOOD, MA -- (Marketwired) -- 06/16/15 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that it will be added to the [Russell MicroCap® Index](#) at the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to a preliminary [list of additions](#) posted June 12, 2015.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"We are very pleased to have been selected by FTSE Russell for listing on their microcap index," stated Yuval Cohen, Ph.D., Chief Executive Officer of the Company. "Being part of the Russell MicroCap Index will contribute to increasing the Company's visibility and further broaden our shareholder base. We believe that inclusion in indices such as this are important to improving overall shareholder value, and we look forward to garnering additional visibility as we advance our three Phase 2 clinical trials with our lead product candidate [Resunab™](#) for the treatment of [diffuse cutaneous systemic sclerosis](#) (scleroderma), [cystic fibrosis](#) and [dermatomyositis](#)."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately \$5.7 trillion in assets are benchmarked to the Russell's U.S. indexes. For more information on the Russell 1000 and the Russell indexes reconstitution, go to "Recon Central" section on the [FTSE Russell website](#).

### **About Resunab™**

Resunab™ is a novel synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab triggers resolution of inflammation by increasing production of "Specialized Pro-resolving Lipid Mediators of Inflammation" and anti-inflammatory mediators, while reducing production of pro-inflammatory mediators and reducing numbers of immune cells in affected

tissues. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

### ***About Corbus***

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis ("scleroderma"), and skin-predominant dermatomyositis in 2015. For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com).

### ***Forward-Looking Statements***

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

### ***Investor Contact***

Jenene Thomas  
Jenene Thomas Communications, LLC  
Phone: +1 (908) 938-1475  
Email: [Email Contact](#)

### ***Media Contact***

David Schull or Marissa Goberdhan  
Russo Partners, LLC  
Phone: +1 (858) 717-2310  
Email: [Email Contact](#)  
Email: [Email Contact](#)

Source: Corbus Pharmaceuticals Holdings, Inc.